Cargando…

Experience with direct-acting antivirals in genotype 1–5 infected chronic hepatitis C patients in Turkey

BACKGROUND: Hepatitis C virus (HCV) can cause chronic liver disease, hepatic cirrhosis, hepatocellular carcinoma, liver transplantation, and death. Early diagnosis and treatment are thus vital. OBJECTIVES: We aimed to investigate the sustained virological response (SVR) rates in chronic hepatitis C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sahin, Ahmet, Akay, Ozlem
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	King Faisal Specialist Hospital and Research Centre 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560371/ https://www.ncbi.nlm.nih.gov/pubmed/37805816 http://dx.doi.org/10.5144/0256-4947.2023.308

Ejemplares similares

Direct-Acting Antivirals in Chronic Hepatitis C Genotype 4 Infection in Community Care Setting
por: Gayam, Vijay, et al.
Publicado: (2018)

Management of hepatitis C genotype 4 in the directly acting antivirals era
por: Hathorn, Emma, et al.
Publicado: (2016)

Direct-acting Antiviral Regimens for Patients with Chronic Infection of Hepatitis C Virus Genotype 3 in China
por: Wang, Xiaozhong, et al.
Publicado: (2021)

Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5
por: Liu, Chen-Hua, et al.
Publicado: (2022)

Systematic Review with Meta-Analysis: Efficacy and Safety of Direct-Acting Antivirals for Chronic Hepatitis C Genotypes 5 and 6
por: Due, Ong The, et al.
Publicado: (2019)

In a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkey
por: Sarıgül Yıldırım, Figen, et al.
Publicado: (2022)

Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents
por: Zanaga, L.P., et al.
Publicado: (2016)

Direct‐acting antiviral therapy for chronic hepatitis C virus genotype 4 infection: Exploring new regimens
por: Toyoda, Hidenori
Publicado: (2019)

Three Children Treated with Direct-acting Antivirals for Chronic Hepatitis C Virus Genotype 1b Infection
por: Ohya, Kazuki, et al.
Publicado: (2019)

Economic evaluation of direct‐acting antivirals for the treatment of genotype 3 hepatitis C infection in Singapore
por: Wong, Yu‐Jun, et al.
Publicado: (2019)

Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection
por: Kanda, Tatsuo, et al.
Publicado: (2014)

Efficacy and safety of direct-acting antiviral therapy for chronic hepatitis C genotype 6: A meta-analysis
por: Luo, Aoran, et al.
Publicado: (2019)

Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam
por: Due, Ong The, et al.
Publicado: (2020)

Direct Acting Antivirals in Patients with Chronic Hepatitis C and Down Syndrome
por: Yoo, Eric R., et al.
Publicado: (2016)

The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C
por: Yang, Christine Hong Ting, et al.
Publicado: (2017)

Current therapy for chronic hepatitis C: The role of direct-acting antivirals
por: Li, Guangdi, et al.
Publicado: (2017)

Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges
por: Zeng, Haiyan, et al.
Publicado: (2020)

Efficacy of direct-acting antiviral treatment for chronic hepatitis C: A single hospital experience
por: Kaneko, Rena, et al.
Publicado: (2018)

Genotypes of Hepatitis C Virus and Efficacy of Direct-Acting Antiviral Drugs among Chronic Hepatitis C Patients in a Tertiary Care Hospital
por: Hawsawi, Nahed Mohammed, et al.
Publicado: (2023)

The Impact of Direct-Acting Antiviral Agents on Cytomegalovirus Reactivation in Chronic Hepatitis C Infection
por: Dawood, Reham M, et al.
Publicado: (2022)

Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam
por: Nguyen, Dung Thanh, et al.
Publicado: (2020)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
por: Karayiannis, Peter
Publicado: (2012)

Barriers to care for chronic hepatitis C in the direct-acting antiviral era: a single-centre experience
por: Nguyen, Peter, et al.
Publicado: (2017)

Direct-acting antivirals for chronic hepatitis C treatment: The experience of two tertiary university centers in Brazil
por: Lourenço, Mariana Sandoval, et al.
Publicado: (2022)

Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis C
por: Gallach, Marta, et al.
Publicado: (2018)

Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy
por: Huang, Chung-Feng, et al.
Publicado: (2020)

Evaluation of fibrosis in chronic hepatitis C patients treated with direct-acting antivirals
por: Tufan, Ayse Gokcen, et al.
Publicado: (2020)

Cardiovascular Risk in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals
por: Ramadan, Mohammad Said, et al.
Publicado: (2022)

Direct-acting antiviral retreatment patterns for hepatitis C
por: Hasan, Shaquib Al, et al.
Publicado: (2022)

Development of Autoimmune Hepatitis during Direct-acting Antiviral Therapy for Chronic Hepatitis C Virus Infection
por: Matsumoto, Kotaro, et al.
Publicado: (2018)

Hepatic fibrosis changes in patients with chronic hepatitis C infection who respond to direct-acting antivirals
por: Alswat, Khalid, et al.
Publicado: (2022)

Cost–utility of sofosbuvir/velpatasvir versus other direct-acting antivirals for chronic hepatitis C genotype 1b infection in China
por: Yun, Haoya, et al.
Publicado: (2020)

Efficacy and Safety of Direct-Acting Antivirals in Elderly Patients with Chronic Hepatitis C: A Nationwide Real-Life, Observational, Multicenter Study from Turkey
por: Önlen, Yusuf, et al.
Publicado: (2022)

Distribution and Predominance of Genotype 3 in Hepatitis C Virus Carriers in the Province of Kahramanmaras, Turkey
por: Caliskan, Ahmet, et al.
Publicado: (2015)

Direct-acting antivirals for acute hepatitis C in HIV-infected MSM
por: Millard, James Daniel, et al.
Publicado: (2016)

Hepatitis C virus infection in children in the era of direct-acting antiviral
por: Pawlowska, Malgorzata, et al.
Publicado: (2018)

Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease
por: Iliescu, Elena Laura, et al.
Publicado: (2020)

Safety and effectiveness of direct-acting antivirals in patients with chronic hepatitis C and chronic kidney disease
por: Ryu, Ji Eun, et al.
Publicado: (2022)

Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C: Open Issues and Future Perspectives
por: Chae, Hee Bok, et al.
Publicado: (2013)

Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals
por: Alexopoulou, Alexandra, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_st4v1qgapkp6f7ugnu2qfi1bo4